Stock Analiz

Tarsus Pharmaceuticals, Inc. (TARS) financials: revenue, earnings and cash flow

Fiscal 2018–2025 + TTM · from SEC filings · data as of November 16, 2026

Summary

Net income in fiscal 2025 was -$66M, a net margin of -14.7%; the best year in this period was 2018 with -$1M.

Over the twelve months to September 30, 2026, revenue was $682M and net income -$702M.

Free cash flow was -$22M in fiscal 2025 and positive in 1 of the 8 years shown.

Revenue, profit and cash flow by year

Revenue
2020: $020202021: $57M20212022: $26M20222023: $17M20232024: $183M20242025: $451M2025$451M
Net income
2018: -$1M20182019: -$5M20192020: -$27M20202021: -$14M20212022: -$62M20222023: -$136M20232024: -$116M20242025: -$66M2025-$66M
Free cash flow
2019: -$4M20192020: -$22M20202021: $3M20212022: -$50M20222023: -$119M20232024: -$85M20242025: -$22M2025-$22M
EPS (diluted)
2019: $-1.9820192020: $-4.3220202021: $-0.6720212022: $-2.5220222023: $-4.6220232024: $-3.0720242025: $-1.592025$-1.59

Income statement

Fiscal yearTTM20252024202320222021202020192018
Revenue$682M$451M$183M$17M$26M$57M$0——
Gross profit—————————
Operating income-$696M-$71M-$121M-$143M-$63M-$12M-$27M-$4M—
Net income-$702M-$66M-$116M-$136M-$62M-$14M-$27M-$5M-$1M
EPS (diluted)$-15.86$-1.59$-3.07$-4.62$-2.52$-0.67$-4.32$-1.98—
R&D$116M$64M$53M$50M$43M$42M$19M$3M—
Revenue growth—+146.7%+948.6%−32.4%−54.7%————

Cash flow

Fiscal yearTTM20252024202320222021202020192018
Operating cash flow$50M-$12M-$83M-$117M-$49M$4M-$21M-$4M—
Capital spending-$17M-$10M-$2M-$2M-$506000-$586000-$456000-$175000—
Free cash flow$32M-$22M-$85M-$119M-$50M$3M-$22M-$4M—
Dividends paid—$0$0$0$0$0$0$0$0
Buybacks—————————
Stock-based pay$67M$42M$28M$20M$13M$8M$839000$18000—

Balance sheet

Fiscal yearTTM20252024202320222021202020192018
Cash—$417M$291M$227M$217M$172M$168M$58M$2M
Debt—$83M$72M$32M$20M$1M$831000$164000—
Equity—$343M$225M$197M$193M$167M$166M-$6M-$1M
Total assets—$562M$377M$265M$228M$179M$172M$58M—
Shares (diluted)46M42M38M29M25M21M6M2M—

Margins and returns

Fiscal yearTTM20252024202320222021202020192018
Gross margin—————————
Operating margin-102.0%-15.7%-65.9%-820.5%-242.9%-21.3%———
Net margin-102.9%-14.7%-63.2%-778.9%-240.5%-24.2%———
FCF margin4.8%-4.9%-46.2%-682.0%-191.9%5.5%———
ROIC—-13.2%-40.6%-62.6%-29.4%-5.7%-12.8%——
ROE—-19.3%-51.5%-69.0%-32.2%-8.3%-16.2%77.8%97.4%

Frequently asked questions

What is Tarsus Pharmaceuticals’s annual revenue?

$451M in fiscal 2025 and $682M over the twelve months to September 30, 2026.

How much profit does Tarsus Pharmaceuticals make?

Net income was -$66M in fiscal 2025 (net margin -14.7%).

Is Tarsus Pharmaceuticals’s revenue growing?

Yes: revenue rose 146.7% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.